At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 122 enrolled
Drug / intervention
Standard of Care as per attending physician +1 moredrug
Likely dose
5mg rapidly dissolving olanzapinefrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Oral Rapidly Dissolving Olanzapine for Acute Primary Headache in the Emergency Department Setting: A Feasibility Trial
In Brief
A Phase 4 clinical trial evaluating Standard of Care as per attending physician and 5mg rapidly dissolving olanzapine for Headache. Completed, enrolled 122 participants across 1 site.
Detailed Summary
This trial is a prospective, randomized, feasibility trial with the primary aim of comparing how well oral rapidly dissolving olanzapine controls primary headache pain when compared to the current treatment strategies used in emergency departments which often require intravenous or intramuscular medications.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeadache
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJul 2016
First PostedFeb 2017
Primary CompletionMay 2018
Study CompletionMay 2018
TodayJul 2026
First PostedFeb 28, 2017
Enrollment StartJul 1, 2016
Primary CompletionMay 17, 2018
Study CompletionMay 20, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.3 years ago
Interventions
Standard of Care as per attending physiciandrug
Patients are randomized to standard of care medication (as determined by attending physician)
5mg rapidly dissolving olanzapinedrug
5mg rapidly dissolving olanzapine